Effect of pyridostigmine on growth hormone and IGF-1 levels and outcomes of controlled ovarian stimulation cycle in women with poor ovarian response

What Was Tested

Researchers studied IGF-1 LR3 in this randomized controlled trial publication.

This study aimed to evaluate the effect of Pyridostigmine on IGF-1 and GH levels and the outcomes of COS cycles in women with POR.

Why It Was Studied

Iranian Registry of Clinical Trials (IRCT).

Registration date: 2023-08-05, Registration number: IRCT20100518003950N8.

Who Took Part

The study group was 110 women.

PubMed indexes the participants as adults, women only.

A total of 110 eligible women were randomly allocated to Pyridostigmine (n: 55) and control (n: 55) groups.

How the Study Was Run

In design terms this was a randomized study.

Because people in this IGF-1 LR3 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Also, IGF-1 and GH levels were measured at three time points: baseline, on the 5th day of the cycle, and on the trigger day.

What Was Measured

PubMed files the paper under topics including Ovulation Induction, Insulin-Like Growth Factor I, Pyridostigmine Bromide, Human Growth Hormone, Cholinesterase Inhibitors and Infertility, Female.

The authors tagged it with the keywords Acetylcholinesterase Inhibitors, Assisted reproductive technology, Controlled ovarian stimulation and Poor ovarian response.

What This Means in Plain Language

The paper is a randomized study of IGF-1 LR3 in 110 women.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Archives of gynecology and obstetrics), a journal based in Germany.

More context: the IGF-1 LR3 compound page, all human trials.